Skip to main content
. Author manuscript; available in PMC: 2019 Aug 19.
Published in final edited form as: Methods Mol Biol. 2019;1911:481–503. doi: 10.1007/978-1-4939-8976-8_33

Table 3.

Summary of HCV immunization studies performed in humanized mice

Expression approach Virus Immunization
Genetically humanized mice Adenovirus HCV-Cre expressing genotypes 1b, 2a, or 4a structural proteins [43] Active
In vitro neutralization assay with chimeric HCVcc panel covering all seven HCV genotypes; BiCre-Jc1 (genotype 2a) in vivo [52] Active
HCV-Cre recombinase expressing structural proteins of Con1 (genotype 1b) or Jc1 (genotype 2a) [80] Passive
BiCre-Jc1 (genotype 2a) [102] Passive
Mouse Virus Immunization
Human liver chimeric mice uPA/SCID Heterologous HCV inoculum from an HCV genotype 1a infected patient [94] Passive
Patient-derived genotype 1b [96] Passive
H77C (genotype 1a), ED43 (genotype 4) [104]) Passive
Prevention experiments: genotype 1b or genotype 4 HCV-infected serum; treatment experiments: Jc1 (genotype 2a), VL-JFH1 (genotype 1b/2a chimera), genotype 2a serum, genotype 4 serum [106] Passive
J6/JFH1 (genotype 2a) [107] Passive
Mouse-passaged H77C (genotype 1a) [108] Passive
FNRG PXB-mouse (cDNA-uPA/SCID) H77 (genotype 1a), J6/JFH1 (genotype 2a) [102] Passive
H77S (genotype 1a) [103] Passive
Mouse-passaged HCR6 (genotype 1b) [105] Passive